The expression level of SLC2A10 was significantly correlated with worse survival of patients with gastric cancer, ovarian cancer, bladder cancer, breast cancer, esophageal adenocarcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, lung cancer, pancreatic ductal adenocarcinoma, stomach adenocarcinoma and uterine corpus endometrial carcinoma (Fig. 3A–K). Here, SLC2A10 is linked to urinary bladder carcinoma.